Brief: Diffusion Announces Positive Effects In Altitude Trial

CervoMed

23/06/2022 12:39

June 23 (Reuters) - Diffusion Pharmaceuticals Inc  DFFN.O :
    * DIFFUSION PHARMACEUTICALS ANNOUNCES POSITIVE EFFECTS IN
ALTITUDE
TRIAL
    * DIFFUSION PHARMACEUTICALS INC - POSITIVE EFFECTS ON
OXYGENATION
OBSERVED WITH 2.5 MG/KG DOSE AT END OF EXERCISE INTERVAL
    * DIFFUSION PHARMACEUTICALS INC - TSC WAS SAFE AND
WELL-TOLERATED
BY ALL SUBJECTS WITH NO SERIOUS ADVERSE EVENTS REPORTED
    * DIFFUSION PHARMACEUTICALS - DISCUSSING CLINICAL PROTOCOL
DESIGN
FOR PHASE 2 HYPOXIC TUMOR TRIAL WITH FDA,EXPECT TO INITIATE
TRIAL IN H2 2022

Source text for Eikon:  ID:nGNX5g0dl1 
Further company coverage:  DFFN.O 

 ((Reuters.Briefs@thomsonreuters.com;))